Swedish Orphan Biovitrum AB (publ)

OM:SOBI Stock Report

Market Cap: SEK 104.3b

Swedish Orphan Biovitrum Future Growth

Future criteria checks 3/6

Swedish Orphan Biovitrum is forecast to grow earnings and revenue by 16.7% and 9.3% per annum respectively. EPS is expected to grow by 17.4% per annum. Return on equity is forecast to be 13.5% in 3 years.

Key information

16.7%

Earnings growth rate

16.93%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate9.3%
Future return on equity13.49%
Analyst coverage

Good

Last updated12 May 2025

Recent future growth updates

Swedish Orphan Biovitrum AB (publ) Just Recorded A 30% EPS Beat: Here's What Analysts Are Forecasting Next

May 02
Swedish Orphan Biovitrum AB (publ) Just Recorded A 30% EPS Beat: Here's What Analysts Are Forecasting Next

Swedish Orphan Biovitrum AB (publ) Just Recorded A 8.0% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 07
Swedish Orphan Biovitrum AB (publ) Just Recorded A 8.0% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

Swedish Orphan Biovitrum AB (publ) Just Recorded A 30% EPS Beat: Here's What Analysts Are Forecasting Next

May 02
Swedish Orphan Biovitrum AB (publ) Just Recorded A 30% EPS Beat: Here's What Analysts Are Forecasting Next

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Price In Tune With Earnings

Apr 18
Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Price In Tune With Earnings

Does Swedish Orphan Biovitrum (STO:SOBI) Deserve A Spot On Your Watchlist?

Feb 28
Does Swedish Orphan Biovitrum (STO:SOBI) Deserve A Spot On Your Watchlist?

Swedish Orphan Biovitrum AB (publ) Just Recorded A 8.0% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 07
Swedish Orphan Biovitrum AB (publ) Just Recorded A 8.0% EPS Beat: Here's What Analysts Are Forecasting Next

Swedish Orphan Biovitrum (STO:SOBI) Has A Pretty Healthy Balance Sheet

Jan 21
Swedish Orphan Biovitrum (STO:SOBI) Has A Pretty Healthy Balance Sheet

Earnings Tell The Story For Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Dec 30
Earnings Tell The Story For Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
author-image

Innovative Product Launches And Global Expansion Drive Bright Future In Sobi's Portfolio

Nov 20 Expansion of hematology and immunology divisions, with new product launches, drives strong revenue growth and market positioning.

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Oct 27
Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19
Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jun 24
Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Earnings and Revenue Growth Forecasts

OM:SOBI - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202735,0307,6529,48710,72010
12/31/202631,6096,1418,2299,39211
12/31/202528,1674,6607,3148,41811
3/31/202526,2363,9605,1417,427N/A
12/31/202426,0273,8854,3837,388N/A
9/30/202425,4353,5143,2556,663N/A
6/30/202423,7102,1455,0566,716N/A
3/31/202423,1402,1422,3284,743N/A
12/31/202322,1232,409-4734,470N/A
9/30/202321,2702,7697435,291N/A
6/30/202320,1003,1251204,977N/A
3/31/202319,1043,1623374,915N/A
12/31/202218,7902,6383,0994,576N/A
9/30/202217,6962,4933,1454,804N/A
6/30/202217,4582,5163,3634,317N/A
3/31/202216,7932,5264,9795,415N/A
12/31/202115,5292,6795,1005,470N/A
9/30/202115,2142,9401,4054,066N/A
6/30/202114,4242,7443784,190N/A
3/31/202114,2832,7598194,739N/A
12/31/202015,2613,2451,0744,926N/A
9/30/202015,5703,1033,1015,185N/A
6/30/202015,5303,3675,7475,799N/A
3/31/202015,6223,5835,1765,132N/A
12/31/201914,2483,304-5,1713,634N/A
9/30/201911,9292,539-4,8683,195N/A
6/30/201911,3132,620-6,5262,912N/A
3/31/201910,4402,806-7,2332,201N/A
12/31/20189,1392,418N/A2,090N/A
9/30/20188,4432,181N/A1,810N/A
6/30/20187,7291,881N/A1,678N/A
3/31/20187,0791,462N/A1,287N/A
12/31/20176,5111,149N/A1,333N/A
9/30/20175,927865N/A1,103N/A
6/30/20175,497677N/A604N/A
3/31/20175,327703N/A431N/A
12/31/20165,204802N/A343N/A
9/30/20164,727716N/A329N/A
6/30/20164,341585N/A493N/A
3/31/20163,636291N/A573N/A
12/31/20153,22865N/A507N/A
9/30/20153,11959N/A547N/A
6/30/20153,000108N/A426N/A
3/31/20152,899136N/A268N/A
12/31/20142,607-268N/A234N/A
9/30/20142,513-263N/A185N/A
6/30/20142,364-373N/A86N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SOBI's forecast earnings growth (16.7% per year) is above the savings rate (1.3%).

Earnings vs Market: SOBI's earnings (16.7% per year) are forecast to grow faster than the Swedish market (16.4% per year).

High Growth Earnings: SOBI's earnings are forecast to grow, but not significantly.

Revenue vs Market: SOBI's revenue (9.3% per year) is forecast to grow faster than the Swedish market (4.3% per year).

High Growth Revenue: SOBI's revenue (9.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SOBI's Return on Equity is forecast to be low in 3 years time (13.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/12 23:41
End of Day Share Price 2025/05/12 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Swedish Orphan Biovitrum AB (publ) is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Xue ChenBarclays
Rosie TurnerBarclays